09
Dec

With its designs on AstraZeneca at least temporarily abandoned, Pfizer has set out to create an immuno-oncology portfolio of its own, signing a deal with a Belgian biotech to get its hands on treatments that promise to sharpen the body’s anticancer weaponry.

…read more

Source: Pfizer strikes another immunotherapy deal to widen its oncology pipeline

    

0 No comments